Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning

NCT07332923 · tracked via the Priya Life Science China tracker

Sponsor

First Affiliated Hospital of Fujian Medical University

Phase

Observational

Started

2024-08-01

Last updated

2026-01-12

Condition(s) studied

Renal Clear Cell CarcinomaHIF-2αRadiomicsNomogram

Study summary

This project aims to conduct a multicenter retrospective study to collect clinical, CT imaging, and pathological data from patients. A comprehensive data management system will be established, and radiomic features will be extracted to integrate and analyze multicenter data. We will develop a predictive model based on CT radiomic features and perform both internal and external cohort validation. The model will predict HIF-2α expression levels and clinically relevant prognostic factors in ccRCC, enabling precise identification of patient populations responsive to the HIF-2α antagonist Belzutifan, thereby facilitating personalized treatment decisions, minimizing unnecessary therapeutic risks, and ultimately improving patient quality of life and clinical outcomes.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Pathologically confirmed clear cell renal cell carcinoma (ccRCC) * Availability of comprehensive clinical, pathological, and follow-up information * Access to preoperative non-contrast and contrast-enhanced CT images through the PACS database * Adequately preserved pathological slides for subsequent immunohistochemical (IHC) or tissue microarray analysis * Minimum of one post-treatment follow-up with documented treatment response or efficacy evaluation Exclusion Criteria: * Patients considered ineligible for treatment owing to severe comorbid conditions or inability to undergo any therapeutic intervention * Patients with concurrent malignancies, including prior treatment for other cancers or presence of untreated active malignancies * Patients with inadequate CT image quality or missing imaging data * Patients with missing or incomplete clinical, pathological, or follow-up information

Primary outcome measure(s)

HIF-2α Expression Levels in Clear Cell Renal Cell Carcinoma — 1 week

Trial sites (1)

Facility	City	Region	Status
first hospital affiliated of Fujian medical university	Fuzhou	Fujian

More First Affiliated Hospital of Fujian Medical University trials in China

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer Recruiting

Analysis of Immediate Urinary Continence Predictors After RS-RARP Active, not recruiting

68Ga-AAZTA-NI-093 PET/CT: First-in-human Study Recruiting

Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer Recruiting

A Registered Cohort Study on Amyotrophic Lateral Sclerosis Recruiting

Other trials for the same condition

CD70-targeted immunoPET Imaging of Malignant Cancers Recruiting

Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics Starting soon

Multimodal Exercise Therapy for Non-Surgical Intervention of Nonspecific Low Back Pain. Starting soon

Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical Parameters Active, not recruiting

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07332923 on ClinicalTrials.gov ↗ ← All trials in China